Treats unresectable hepatocellular carcinoma (uHCC). Sold as Imjudo. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 2 applications for Tremelimumab-Actl (sold as Imjudo), first approved Oct 21, 2022, with 0 new uses approved and 0 published complete response letters.
| Imjudo | Part B | $61.7M | +27% | 1,551 |
| Imjudo | Part D | $3.5M | +26% | 83 |
| Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular CarcinomaLocally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 · OHSU Knight Cancer Institute | Phase 2 | Not yet recruiting | Apr 6, 2026 |
| Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialLung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 · City of Hope Medical Center | Phase 2 | Recruiting | Dec 17, 2025 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialAdvanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 · NRG Oncology | Phase 3 | Recruiting | Sep 10, 2025 |
| Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic CholangiocarcinomaLocally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma · Mayo Clinic | Phase 1 | Recruiting | Sep 28, 2023 |
| Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLCNon Small Cell Lung Cancer, NSCLC, Stage III · Stanford University | Phase 3 | Recruiting | Oct 14, 2020 |
| Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal CancerFallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma · National Cancer Institute (NCI) | Phase 2 | Active, not recruiting | Jul 29, 2019 |
| Targeted Pathway Inhibition in Patients With Pancreatic CancerLocally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma · OHSU Knight Cancer Institute | Early phase 1 | Recruiting | Jul 2, 2019 |
| Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerAnatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma · National Cancer Institute (NCI) | Phase 2 | Recruiting | Jul 31, 2018 |
| Oct 21, 2022 | ImjudoBLA 761289 · New molecular entity | Astrazeneca AB | 5 | Marketed |
| Nov 10, 2022 | ImjudoBLA 761270 · New indication | Astrazeneca AB | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA